endo-postop-igf1-random-gh-12wks

name	endo-postop-igf1-random-gh-12wks
description	Measures serum IGF-1 and a random GH level at 12 weeks or later after transsphenoidal surgery for acromegaly to evaluate biochemical remission. Trigger phrases: “postoperative follow‑up at 12 weeks”, “assess remission after surgery”, “check IGF‑1 and random GH”.

Measure IGF-1 and random GH at 12 weeks post‑op

STEP 1 — Gather Information

Collect date of transsphenoidal surgery, surgical approach, postoperative medications, baseline preoperative IGF‑1 and GH if available, current symptoms (headache, sweating, fatigue), and ensure no acute illness or medication that could affect IGF‑1.
Action: Proceed to step 2.

STEP 2 — Rule In / Rule Out

Determine whether the postoperative IGF‑1 level is age‑ and sex‑normalized using the assay‑specific reference range.

• If IGF‑1 is normal → go to step 3A.
• If IGF‑1 is elevated or equivocal → go to step 3B.
  Action: Branch based on IGF‑1 result.

STEP 3 — Classify or Stratify

3A (IGF‑1 normal): Measure random GH; if random GH <1.0 µg/L → classify as biochemical remission; if random GH ≥1.0 µg/L → classify as discordant (normal IGF‑1 with detectable GH).
3B (IGF‑1 elevated): Classify as persistent biochemical disease regardless of GH.
Action: Move to step 4 with the classification.

STEP 4 — Decide

• Biochemical remission: Continue routine surveillance (clinical review and IGF‑1 every 6‑12 months); no additional medical therapy needed.
• Discordant (normal IGF‑1, GH ≥1.0 µg/L): Repeat IGF‑1 and random GH in 8‑12 weeks; consider trial of medical therapy if GH remains elevated.
• Persistent disease (elevated IGF‑1): Obtain postoperative MRI (if not done) and discuss adjuvant medical therapy (SRL, pegvisomant, or repeat surgery).
  Action: Implement the decided plan.

Clinical Guardrails / Mimics / Pitfalls

Do not interpret a single random GH as diagnostic; IGF‑1 assay variability requires using the same laboratory and method; avoid testing before 12 weeks due to postoperative GH/IGF‑1 fluctuations; do not rely on IGF‑1 in patients with untreated renal or hepatic failure, malnutrition, or hypothyroidism as these can cause false‑low or false‑high values; never omit postoperative imaging when IGF‑1 remains elevated.

Concrete Clinical Example

A 48‑year‑old man had endoscopic transsphenoidal resection for a GH‑secreting macroadenoma. At the 12‑week postoperative visit his IGF‑1 was age‑normalized (0 SD) and random GH was 0.4 µg/L. He was classified as biochemical remission and placed on annual IGF‑1 surveillance with symptom review.

Source: Acromegaly: An Endocrine Society Clinical Practice Guideline, Katznelson et al., Endocrine Society, 2014, https://doi.org/10.1210/jc.2014-2700